Seracal, based on Lym-X-Sorb, contains a proprietary lipid technology invented by David Yesair Ph.D. and exclusively licensed by Vytala
Vytala, a healthcare-focused food technology company, announced a series of key achievements signifying commercial momentum and early market leadership. Following the launch of Seracal in November, monthly sales growth has exceeded 50%, driven by strong clinician interest, patient need, and broad coverage by US healthcare insurers.
Dr. Debora Duro, Program Director, Pediatric Gastroenterology, Hepatology and Nutrition at Broward Health, has prescribed Seracal to multiple patients and shares: “Seracal is amazing. I have patients with diagnoses ranging from intestinal failure to faltering weight, and most have experienced weight gain within the first month. Parents are overjoyed, the product is easy to use, and children are gaining weight after months of struggle.”
Market demand for Seracal has surpassed initial forecasts with a 90% reorder rate – further confirming strong patient acceptance and sustained clinical adoption. Seracal was recently approved by 3 HealthWell Foundation disease funds within Vitamins and Supplements. This partnership expands access and provides support for patients starting on their Seracal journey.
Seracal is an improved formulation that contains the underlying technology of Lym-X-Sorb, a pioneering nutritional therapy invented by Dr. David Yesair of BioMolecular Products, Inc. that addresses fat malabsorption. Seracal/Lym-X-Sorb was proven to be efficacious and well-tolerated in patients with exocrine pancreatic insufficiency and cystic fibrosis in a large $7 million National Institutes of Health sponsored clinical study. Subjects randomized to Seracal/Lym-X-Sorb experienced improved BMI, as demonstrated by increases in both weight and height velocity. The therapy also improved absorption of essential fatty acids, fat-soluble vitamins and choline.
Health Technology Insights: Harrow Launches VEVYE Access for All
Vytala signed an exclusive worldwide licensing agreement with BioMolecular Products (BMP), gaining rights to Lym-X-Sorb’s proprietary formulation and extensive manufacturing trade secrets. Over $30 million dollars has funded development of the Lym-X-Sorb technology to date. Vytala has made further formulation enhancements, incorporating key taste, texture and stability improvements into Seracal.
A patient with pancreatic cancer describes his experience with Seracal: “I have gained between 8-10 pounds since starting Seracal 6 weeks ago. I believe it has also helped with my chronic pancreatitis, lessening the symptoms of belly pain and back pain. This has allowed me to widen my diet to include foods that I couldn’t eat previously.”
Vytala is actively enrolling subjects into an IRB approved study designed to assess Seracal’s acceptance and clinical outcomes across a broader patient populations. Led by Dr. Carol Ireton-Jones PhD, RDN, CNSC, FASPEN, FAND, an esteemed expert in gastrointestinal nutrition with numerous publications – the multi-center study will measure GI symptoms, weight gain and nutrient absorption in at least 30 patients aged one and older.
Health Technology Insights: SolasCure Enrolls First Patient in Phase II Aurase Wound Trial
Swapna, a healthcare advocate, researcher and adult living with Short Bowel Syndrome, conveyed her excitement about being one of the first patients to enroll in the study: “Living a fulfilling life with tube feeding due to congenital Short Bowel Syndrome, I have always had to be at the mercy of innovation. Participating in Vytala’s early experience program, I can finally be at the forefront of science. I hope Seracal will be the easy and accessible answer to my reduced ability to absorb fat and fat-soluble nutrients, a barrier I have had for 35 years. Maybe I can even live to eat and enjoy nourishing myself with food without all the complications! A goal I have only dreamed of.“
Dr. Ireton-Jones commented, “Anecdotal data provides insight into patient experiences, but in the scientific community, research is essential to generate evidence. That is why we’re conducting this study. We are confident that Seracal’s unique technology will improve fat absorption in patients with a variety of GI conditions, which is why this study is so important.”
Health Technology Insights: IgniteData Launches Data Integration Platform for Clinical Trials
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
